Aztreonam lysine

AUSTIN, Texas and TOKYO, Dec. 1, 2025 /PRNewswire/ -- According to DataM Intelligence, the Cystic Fibrosis (CF) Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 billion in 2023, and is now projected to expand aggressively to USD 35.09 billion by 2033, recording a CAGR of 14.2% during 2025–2033. The surge is driven by transformational advancements in CFTR modulator therapies, higher treatment access across the U.S. and Europe, the expansion of personalized medicine programs, improvements in newborn screening, and stronger R&D investments targeting rare genetic diseases. Cystic fibrosis, a life-long autosomal recessive disorder caused by mutations in the CFTR gene, affects more than 162,000 patients globally, with rising diagnostic rates enabling broader therapeutic adoption. The past five years have shifted the market from symptomatic management to disease-modifying treatments, marking the most significant clinical progress in CF care in decades. Download PDF Brochure: Browse in-depth TOC on "Cystic Fibrosis Therapeutics Market" 71 – Tables 67 – Figures 192 – Pages Precision Medicine, Breakthrough Modulators & Improved Survival Rates Accelerate Market Adoption Cystic fibrosis has moved from a once-fatal childhood disease to a highly treatable chronic condition, thanks to advanced therapeutic classes. Today's market growth is being propelled by three major dynamics: 1. CFTR Modulator Innovations Are Reshaping the Standard of Care CFTR modulators such as ivacaftor, tezacaftor, elexacaftor, and combination regimens have expanded eligibility to nearly 90% of CF patients, dramatically improving lung function, BMI, respiratory exacerbation rates, and life expectancy. 2. Rising Diagnosis Rates and Earlier Intervention With neonatal screening improving globally, early treatment initiation is raising adherence and increasing long-term therapeutic demand. Countries in Europe and Asia have expanded newborn testing coverage by 12–20% YoY. 3. Growth of Symptom-Relief Therapies in Untreated CFTR Mutations A subset of patients still relies on mucolytics, bronchodilators, pancreatic enzyme replacement, and inhaled antibiotics-ensuring sustained demand across legacy CF drug segments. Market Segmentation: By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, Others) CFTR Modulators CFTR modulators represented the dominant segment in 2024, accounting for nearly 72% of total revenue (USD 7.63 billion). This class continues to see explosive uptake because of its disease-modifying capabilities and expanded label approvals across adolescents and pediatric patients. Pancreatic Enzyme Supplements Pancreatic enzyme replacement therapies (PERT) accounted for 11% (USD 1.17 billion). They remain standard-of-care for >80% of CF patients due to chronic exocrine pancreatic insufficiency. Mucolytics Mucolytics contributed 8% (USD 848 million), driven by the sustained use of inhaled agents such as dornase alfa for airway clearance. By Route of Administration (Oral, Inhaled, Parenteral) Oral Oral therapies held 69% (USD 7.31 billion) due to the dominance of oral CFTR modulators. This segment will grow fastest through 2033 driven by life-long use and expanded mutation coverage. Inhaled Inhaled therapies contributed 26% (USD 2.76 billion). This includes inhaled mucolytics, bronchodilators, antibiotics, and other respiratory-support agents still widely used in multidisciplinary CF care. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Hospital Pharmacies Hospital pharmacies captured 58% (USD 6.15 billion) as CF remains primarily managed through specialty centers that coordinate multidisciplinary treatment plans. Retail Pharmacies Retail pharmacies represented 31% (USD 3.28 billion), largely driven by the growth of chronic outpatient CF management and expanded insurance coverage. Online Pharmacies Online pharmacies accounted for 11% (USD 1.17 billion) and are increasing rapidly due to home delivery convenience and improved digital prescription services for chronic diseases. Buy This Report with Year-End Offer ( Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): Regional Outlook: United States: Largest and Fastest-Expanding CF Therapeutics Market The U.S. accounted for 54% of global CF drug sales (USD 5.73 billion in 2024). U.S. Market Highlights CF patient registry size exceeds 40,000, representing 25% of global cases CFTR modulator usage penetration surpasses 88% Government and private insurers expanded coverage for next-generation modulators by 20% YoY CF care center expansions increased pulmonary inpatient capacity by 11% By 2033, the U.S. market is forecast to exceed USD 19 billion. Japan: Rapidly Modernizing CF Treatment Landscape Japan accounted for 6% (USD 636 million) of global value in 2024. Japan Market Dynamics Recent improvements in genetic screening increased CF detection rates by 16% YoY Rising access to imported CFTR modulators and specialty respiratory therapies Hospital-based CF clinics increased multidisciplinary patient management capacity by 14% Japan is on track to surpass USD 2.1 billion by 2033 as availability and early diagnosis improve. Competitive Landscape: Below are revenues and cystic-fibrosis or related respiratory/orphan-drug segment contributions based on public annual reports and investor disclosures. Vertex Pharmaceuticals Incorporated 2023 Revenue: USD 9.87 billion CF Franchise Contribution: > USD 9.3 billion (94% of total company revenue) Vertex is the global leader in CFTR modulators including Trikafta/Kaftrio, Symdeko/Symkevi, and Orkambi. F. Hoffmann-La Roche Ltd 2023 Revenue: USD 66.5 billion Respiratory & Infectious Diseases Portfolio: USD 3.4+ billion Expanding CF pipeline with inhaled and anti-inflammatory therapies. Novartis Pharmaceuticals Corporation 2023 Revenue: USD 45.4 billion Immunology & Respiratory Division: USD 8.1 billion Active in inhaled antibiotic programs and airway clearance technologies. Teva Pharmaceuticals USA, Inc. 2023 Revenue: USD 15.8 billion Respiratory Portfolio Contribution: USD 1.7 billion Strong presence in inhalation therapies supporting CF symptom relief. Gilead Sciences, Inc. 2023 Revenue: USD 27.1 billion Antiviral & Anti-Infective Division: USD 5.8 billion Previously developed Cayston (inhaled aztreonam), widely used for chronic lung infections in CF patients. Buy This Report with Year-End Offer ( Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): The Decade Ahead: What will Define the Future of Cystic Fibrosis Therapeutics The Cystic Fibrosis market is on track for the fastest evolution in its history, driven by: Next-gen CFTR modulators targeting rare mutations Combination RNA therapies for non-responders Gene-editing and gene-replacement programs, particularly using CRISPR Inhaled biologics addressing persistent lung infection Improved lipid nanoparticle (LNP) delivery systems enabling organ-specific targeting Pediatric expansion increasing long-term treatment demand Real-world evidence integration improving precision dosing By 2033, cystic fibrosis care will be defined by personalized molecular therapies, multi-modality regimens, and potentially curative genetic treatments-setting the stage for the CF therapeutics market to become one of the most valuable rare-disease drug markets globally. Related Report: Duchenne Muscular Dystrophy Therapeutics Market Size to Surge from US$2.19 B in 2024 to US$6.64 B by 2033 - 13.2% CAGR. Marfan Syndrome Treatment Market Size to Grow from US$203.5 M in 2023 to US$312.6 M by 2031 - Driven by Rising Diagnosis & Advanced Therapeutic & Surgical Care. Huntington's Disease Market Size to Grow from US$456 M in 2024 to US$3.23 B by 2033 - >7.5% CAGR Signals Surge in Therapeutic & R&D Activity. Sickle Cell Anaemia Testing Market Share to Grow at 12% CAGR - From US$0.43 B in 2024 to Over US$1.5 B by 2032. About DataM Intelligence DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations. To find out more, visit or follow us on Twitter, LinkedIn, and Facebook. Contact: Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Logo: SOURCE DataM Intelligence 4 Market Research LLP 21% more press release views with Request a Demo

BioArctic AB (publ) has announced that the US Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act (PDUFA) action date has been set to August 31, 2025. The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modelling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector (AI). The injection process is expected to take, on average, 15 seconds. The SC-AI 360 mg weekly maintenance regimen will allow patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, to receive weekly doses that are expected to maintain the clinical and biomarker benefits. The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for IV administration, which will make it easier to continue maintenance administration and may contribute to further simplifying the treatment pathway for AD. Leqembi is already approved in the US, Japan, China, Great Britain and other markets. In November 2024, the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval.